# SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access

> **NCT02214134** · — · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 539 (actual)

## Conditions studied

- Any Stage of Lung Cancer (Any Histotype)
- Any Stage of Malignant Pleural Mesothelioma
- Any Stage of Any Thymic Malignancy

## Interventions

- **GENETIC:** Tumour markers testing

## Key facts

- **NCT ID:** NCT02214134
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-22
- **Primary completion:** 2020-10-22
- **Final completion:** 2021-05-12
- **Target enrollment:** 539 (ACTUAL)
- **Last updated:** 2025-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02214134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02214134, "SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02214134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*